OVERVIEW

Multiple Myeloma: Keeping Pace With Unfolding Clinical Data is organized by Med-IQ.

Activity Launch Date: August 22, 2024
Activity End Date: February 21, 2025

Statement of Need:
Annual meetings held by professional societies are a leading venue for the presentation of practice-changing data. The 2024 ASCO annual meeting, a leading oncology conference, took place May 31 to June 4, 2024. Hematologist-oncologists and other members of the multiple myeloma care team need resources to stay apprised of ongoing, potentially practice-changing clinical trials, results of which may help clinicians determine appropriate treatment options for their patients with multiple myeloma

Learning Objectives:
Upon completion, participants should be able to:

  • Discuss emerging clinical data regarding treatments for multiple myeloma
  • Integrate recently released clinical trial data relating to treatments for multiple myeloma into clinical practice
Credits

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Advanced practice providers and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME/CE activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME/CE material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

  • 0.25 AMA PRA Category 1 Credit™
  • TARGET AUDIENCE

    PhysicianPhysician AssistantOncologistsHealthcare ProfessionalsNursesHematologistNurse Practitioners

    SPECIALITIES

    OncologyHematology

    RELATED ONLINE COURSES